Fig. 1

The association of platelets and ESCC immunotherapy response. A Overview of the workflow of proteomic profiling of ESCC immunotherapy cohort. B Heatmap of different abundance of xCell score between S and NS groups. C The representative images of immunohistochemistry (IHC) staining of CD8A and GP1BA expression in S and NS groups. The scale bar indicates 20 μm. D Spearman correlation analysis between CD8+ T-cells xCell score and platelets xCell score. P value was from two-sided Spearman correlation test. E Detection of CD8A and GP1BA in ESCC tumor tissue by multi-color IHC staining. Representative data from ESCC patients were shown. The scale bar indicates 50 or 10 μm. F Kaplan–Meier plots showing significant association of blood platelets counts with overall survival (OS) (upper) and progression-free survival (PFS) (bottom) in the MSK-IMPACT ESCC immunotherapy cohort. G The heatmap displaying the differential expression of proteins and their phosphosites involved in platelet activation, aggregation pathway between the S and NS groups. H The heatmap showing the differential expression of proteins involved in platelet activation, aggregation pathway in the IMvigor210 metastatic urothelial carcinoma immunotherapy cohort between the S and NS groups. I The Spearman correlation between the proteins involved in platelet activation, aggregation pathway and CD8+ T cells xCell score. P value was from two-sided Spearman correlation test. J Correlation between FGA protein expression and immunotherapy objective response rate in the TCGA pan-cancer cohort. P value was calculated by two-sided Spearman correlation test. K The qualification of FGA stained by IHC in the representative samples in the S and NS groups. The scale bar indicates 20 μm. L Systematic diagram summarizing the impact of the mechanism underlying ESCC patients with platelet activation is associated with immunotherapy non-sensitivity